Eli Lilly and Company (LLY)
$
802.83
-16.55 (-2.06%)
Key metrics
Financial statements
Free cash flow per share
-0.0559
Market cap
722 Billion
Price to sales ratio
13.5572
Debt to equity
2.1838
Current ratio
1.2777
Income quality
0.7926
Average inventory
10.2 Billion
ROE
0.8836
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Eli Lilly and Company, established in 1876 and headquartered in Indianapolis, Indiana, discovers, develops, and markets human pharmaceuticals globally. The total costs and expenses for the company are $27,541,000,000.00 reflecting its overall spending on research, development, and various operational activities. The operating income ratio is 0.39 indicating the company's operational profitability margin, showcasing its capacity to manage costs in relation to income generated. Its operational expenses amount to $19,122,700,000.00 encompassing the various costs incurred in pursuing its business objectives. Additionally, the gross profit ratio is 0.81 reflecting the efficiency of the company's production and sales operations amid its diverse product portfolio, which includes treatments for diabetes, various cancers, autoimmune conditions, and mental health disorders. Notable products such as Basaglar, Humalog, Jardiance, Alimta, and Taltz emphasize Lilly's broad impact across multiple therapeutic areas. The diluted EPS is $11.71 accounting for potential share dilution, which is an essential consideration for investors assessing the company's financial health and profitability. In the financial markets, the stock is priced at $751.99 positioning it in the higher-end market and reflecting investor confidence. It has a high average trading volume of 4,601,996.00 indicating strong liquidity that is desirable for both retail and institutional investors. With a large market capitalization of $722,030,480,052.00 the company is a dominant player in the pharmaceutical space, influencing trends and developments within the industry. Eli Lilly is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape through innovative therapies and clinical advancements. Furthermore, it belongs to the Healthcare sector, driving innovation and growth while collaborating with various pharmaceutical and biotechnology firms, which strengthens its position in a competitive environment. The combination of a robust product portfolio and a strategic focus on emerging therapies places Eli Lilly in a favorable position for future success while continuing to meet the evolving needs of patients across the globe.
Is Eli Lilly and Company (LLY) a good investment?
Investing in Eli Lilly and Company (LLY) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Eli Lilly and Company (LLY)'s stock forecast?
Analysts predict Eli Lilly and Company stock to fluctuate between $623.78 (low) and $935.63 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Eli Lilly and Company's market capitalization?
As of 2025-10-17, Eli Lilly and Company's market cap is $722,030,480,052, based on 899,356,626 outstanding shares.
How does Eli Lilly and Company compare to competitors like Johnson & Johnson?
Compared to Johnson & Johnson, Eli Lilly and Company has a Higher Market-Cap, indicating a difference in performance.
Does Eli Lilly and Company pay dividends?
Eli Lilly and Company pays dividends. The current dividend yield is 0.83%, with a payout of $1.50 per share.
How can I buy Eli Lilly and Company (LLY) stock?
To buy Eli Lilly and Company (LLY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LLY. Place an order (Market, Limit, etc.).
What is the best time to invest in Eli Lilly and Company?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Eli Lilly and Company stock ever split?
Eli Lilly and Company's last stock split was 2:1 on 1997-10-16.
How did Eli Lilly and Company perform in the last earnings report?
Revenue: $45,042,700,000 | EPS: $11.76 | Growth: 101.72%.
Where can I find Eli Lilly and Company's investor relations reports?
Visit https://www.lilly.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Eli Lilly and Company?
You can explore historical data from here
What is the all-time high and low for Eli Lilly and Company stock?
All-time high: $972.53 (2024-08-22) | All-time low: $220.20 (2021-09-28).
What are the key trends affecting Eli Lilly and Company stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
proactiveinvestors.com
Eli Lilly and Co (NYSE:LLY) will report its third quarter 2025 earnings next Thursday, with Bank of America analysts closely watching how the company's obesity and diabetes treatments are performing amid ongoing policy debates over US drug pricing. The firm believes the drugmaker's upcoming report could offer insight into the company's key brands while highlighting broader industry trends affecting margins and growth.
fool.com
Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 million for the quarter ended September 30, according to an SEC filing released on Friday.
fool.com
On October 17, 2025, Sapient Capital LLC disclosed a purchase of 259,392 Eli Lilly and Company (LLY -1.94%) shares, for a total transaction value of $193,028,908.
seekingalpha.com
Eli Lilly (NYSE:LLY) is up by ~30% since I last checked on it in August, with further upside potential remaining. Three potential developments can catalyse the stock further to achieve this upside, or not. An agreement with the US government on tariffs and further positive trial results can spark a rally for LLY.
investors.com
Eli Lilly said Friday a combination using Verzenio reduced the risk of death by nearly 16% over two years for breast cancer patients.
fool.com
Eli Lilly (LLY -0.97%) and Viking Therapeutics (VKTX -1.02%) offer investors the chance to invest in one of today's highest-potential industries: weight loss drugs. The market for these products, worth about $28 billion right now, is forecast to grow to $95 billion by 2030, according to Goldman Sachs Research.
zacks.com
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
forbes.com
In the last decade, Eli Lilly stock (NYSE: LLY) has returned $47 billion to its shareholders via dividends and buybacks. This shareholder-centric approach has delivered solid results in 2025, with the stock posting 9% year-to-date returns, despite experiencing some volatility from its peak of $937 earlier in the year, while demonstrating remarkable resilience in the face of increased competition in the diabetes and obesity treatment markets.
fool.com
Eli Lilly (LLY -0.82%) has been one of the best-performing healthcare giants over the past decade. It now stands as the largest in the sector by market cap.
fool.com
Independence Bank of Kentucky disclosed a purchase of 4,193 shares of Eli Lilly and Company (NYSE: LLY), estimated at $3.12 million based on the average price for the quarter, in its SEC filing for the period ended September 30, 2025.
See all news
